Investing Profile

Cillian King

VCInvestor
Managing Director at EQT Group
eqtgroup.com/about/people/cil...Amsterdam, Netherlands
Photo of Cillian King, Managing Director at EQT Group

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Massachusetts Institute of Technology Network
162 CONNECTIONS
VU University Amsterdam Network
42 CONNECTIONS
EQT Group Network
35 CONNECTIONS
EQT Group Network
35 CONNECTIONS
EQT Group Network
35 CONNECTIONS
cb
EQT Group Managing Director
$11.0M - $65.0M
$25.0M
1
CompanyStageDateRound SizeTotal Raised
QurAlis
Series BMar 2023$88M
$140M
Co-investors: Amy Schulman (Polaris Partners), Jeffrey Moore (MP Healthcare Venture Management), Johannes Fruehauf (Mission BioCapital), Philip Scheltens (EQT Group), Roel Bulthuis (Syncona Limited), Stephen Thompson (Brandon Capital Partners), Laia Crespo (Sanofi Ventures)
Managing Director EQT Group2022 - Present
Board Member Muna TherapeuticsPresent
Board Member Allero Therapeutics BVPresent
Team leader | Life Sciences Catalyze GroupPresent
Investment Manager Swanbridge CapitalPresent
Board Member Pan Cancer TPresent
Board Member Sairopa B.V.Present
Board Member QurAlisPresent
Research Fellow Massachusetts Institute of TechnologyPresent
Partner EQT GroupPresent
Founder Koala Life SciencesPresent
Investment Manager EQT Group2021 - 2022
Board Member Allero Therapeutics2019 - 2021
Team leader | Life Sciences Catalyze - Carrying Ideas Forward2015 - 2017
Research Fellow Massachusetts Institute of Technology (MIT)2009 - 2009
Intern CNCR, Center for Neurogenomics & Cognitive Research2008 - 2008
Vrije Universiteit Amsterdam (VU Amsterdam) Doctor of Philosophy - PhD Molecular Neurosciences
VU University Amsterdam Doctor of Philosophy - PhD Molecular Neurosciences
BioBusiness Summer School
Sign in with Google →
Sign in with Google →